Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).

Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).

10mg every 6 hours orally as needed for nausea,

12.5-25mg intravenous every 6 hours as needed for nausea.

If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.

Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.

Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.

2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.

4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.

50-150mg orally each day for hand-foot syndrome.

Topical emollient for hand-foot syndrome.

Analgesic for hand foot syndrome as needed.

Replacement therapy for participants with increases in thyroid-stimulating hormone.

2mg daily for prophylaxis of thrombosis.